Revenues increase 243% over the prior year ONSTRYVTM approved by Health Canada in January 2019Listed on CSE in February 2019
KIRKLAND, QC, Feb. 28, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo Pharma") a Canadian specialty pharmaceutical company,
2018 Fourth Quarter Financial and Business Highlights
2018 Full Year Financial and Business Highlights
Key Subsequent Events
"Our growing revenues, coupled with the continued expansion and regulatory progress of our product pipeline, has positioned Valeo Pharma for a successful listing of its shares on the CSE", said Steven Saviuk, Chief Executive Officer. "We look for 2019 to be a transformational year with five product launches planned, the addition of more product rights to innovative drugs and continued revenue growth that will bring us closer to sustainable profitability".
Financial Statements and MD&A
Valeo Pharma's financial statements and Management's Discussion and Analysis for the three and twelve-month periods ended October 31, 2018 are available on SEDAR at www.sedar.com.
About Valeo Pharma
Headquartered in Kirkland, Quebec, Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and oncology, Valeo Pharma has a growing portfolio of innovative products and a complete internal infrastructure to manage these products from registration through commercialization. For more information, please visit www.valeopharma.com
Forward Looking Statements
This document contains some forward-looking information as defined under applicable Canadian securities laws. Forward looking information can generally be identified using forward-looking terminology such as "may", "anticipate", "expect", "intend", "estimate", "continue" or similar terminology. Forward looking information is subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results or performance to be materially different from actual results and are developed based on assumptions about such risks and other factors set out herein.
Non-IFRS Financial Measures
"EBITDA" is a non-IFRS measure. The term EBITDA is defined as net income (loss) before: (i) provision for (recovery of) income taxes; (ii) interest (income) expense and other financing costs; (iii) depreciation of property, plant, and equipment; and (iv) amortization of intangible assets. Management uses EBITDA to provide supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Valeo Pharma inc.
Subscribe to our Free Newsletters!